Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20327732 | 0.90 | NR1I2 (0.33) | ALDH1A1HSD17B10 | |
| SCHEMBL19423930 | 0.80 | TSHR (0.42) | ALDH1A1HSD17B10PRMT5 | |
| SCHEMBL19185240 | 0.76 | PI4KA (0.31) | — | |
| SCHEMBL13554592 | 0.75 | ALDH1A1 (0.41) | ALDH1A1HSD17B10PRMT5 | |
| SCHEMBL29793781 | 0.72 | CYP1A2 (0.39) | ALDH1A1HSD17B10PRMT5 | |
| SCHEMBL27170967 | 0.72 | CYP1A2 (0.39) | ALDH1A1HSD17B10PRMT5 | |
| SCHEMBL19682799 | 0.72 | ALDH1A1 (0.38) | ALDH1A1HSD17B10PRMT5 | |
| SCHEMBL22627564 | 0.72 | ALDH1A1 (0.38) | ALDH1A1HSD17B10PRMT5 | |
| SCHEMBL22292058 | 0.72 | TAS1R3 (0.33) | ALDH1A1TAS1R3TAS1R1HSD17B10PRMT5 | |
| SCHEMBL20193576 | 0.70 | HTR2A (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | ALDH1A1 259/4885TAS1R3 4421/4885TAS1R1 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.